News
FemHealth Ventures closes US$32m fund to back women’s health innovators
FemHealth Ventures aims to invest in women’s health innovations, focusing on drugs, devices, diagnostics, and digital applications
The US venture capital firm FemHealth Ventures has closed a US$32m debut fund to “reimagine” women’s health.
FemHealth Ventures aims to invest in women’s health innovations, focusing on drugs, devices, diagnostics, and digital applications.
The firm says it is the first one of its kind to “reimagine” women’s health to include conditions that affect only women, affect mostly women, or appear differently in women.
According to The Wall Street Journal, the US$32m fundraising came in above the firm’s goal but below the US$50m hard cap as the new venture firm faced obstacles raising its first fund.
Speaking at an Aspen Ideas: Health event in June, FemHealth Ventures managing partner Maneesha Ghiya said she wanted to make a change as she found that women’s health was often overlooked, but she said she was also motivated by her near-death experience she had after giving birth to her daughter.
“I had major complications with my delivery and I almost didn’t make it,” Ghiya explained.
“I had an emergency C-section and although my daughter was healthy, I didn’t feel well. It wasn’t until the next morning that my obstetrician walked in and realised that I had been bleeding internally the whole night and they had missed it.
“She rushed me into the OR and brought in three additional surgeons and they spent two hours with me open trying to find the source of the bleed. They couldn’t find it. They took me to the ICU and I had 10 transfusions. They told my husband they didn’t think I would make it.”
She continued: “Fortunately, my body started catching up with the bleed and I was able to recover, but there are many women that are not so fortunate.
“I felt the way for me to have the most impact, having been a healthcare investor, was to create a vehicle focused specifically around women’s health.”
With FemHealth Ventures, Ghiya said she is looking to back innovators who are developing companies specifically within women’s health.
“We feel there’s a substantial opportunity to do more in this category, have an impact and bring forward extremely compelling innovations to the broader market,” she added.
“A multitude of possibilities for innovation in women’s health exist. We are here to help bring them to life.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






